Instil Bio Inc. (TIL)
undefined
undefined%
At close: undefined

Company Description

Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer.

The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL).

Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 to recognize folate receptor alpha (FOLR1) with indications, including gynecological, non-small cell lung cancer, renal caner, and others.

The company was incorporated in 2018 and is headquartered in Dallas, Texas.

Instil Bio Inc.
Instil Bio Inc. logo
Country United States
IPO Date Mar 19, 2021
Industry Biotechnology
Sector Healthcare
Employees 49
CEO Bronson Crouch

Contact Details

Address:
3963 Maple Avenue
Dallas, Texas
United States
Website https://instilbio.com

Stock Details

Ticker Symbol TIL
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001789769
CUSIP Number 45783C101
ISIN Number US45783C2008
Employer ID 83-2072195
SIC Code 2836

Key Executives

Name Position
Bronson Crouch Chairman & Chief Executive Officer
Dr. Sandeep Laumas M.D. Chief Financial Officer & Chief Business Officer
Dr. Mark E. Dudley Ph.D. Chief Scientific Officer

Latest SEC Filings

Date Type Title
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Nov 13, 2024 S-3 Filing
Nov 13, 2024 10-Q Quarterly Report
Nov 13, 2024 8-K Current Report
Oct 25, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Oct 22, 2024 SC 13D/A [Amend] Filing
Sep 27, 2024 SC 13G Statement of acquisition of beneficial ownership b...
Sep 27, 2024 SC 13G Statement of acquisition of beneficial ownership b...
Sep 23, 2024 4 Filing